Renaissance Technologies LLC Sells 15,900 Shares of Replimune Group, Inc. (NASDAQ:REPL)

Renaissance Technologies LLC lowered its holdings in Replimune Group, Inc. (NASDAQ:REPL) by 9.9% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 145,153 shares of the company’s stock after selling 15,900 shares during the quarter. Renaissance Technologies LLC owned approximately 0.24% of Replimune Group worth $1,306,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the business. Price T Rowe Associates Inc. MD increased its position in shares of Replimune Group by 12.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 6,548,930 shares of the company’s stock worth $53,505,000 after purchasing an additional 699,679 shares in the last quarter. Vanguard Group Inc. grew its position in Replimune Group by 1.2% during the first quarter. Vanguard Group Inc. now owns 2,770,328 shares of the company’s stock valued at $22,634,000 after buying an additional 32,555 shares during the period. Goldman Sachs Group Inc. increased its holdings in Replimune Group by 300.3% in the fourth quarter. Goldman Sachs Group Inc. now owns 2,238,883 shares of the company’s stock valued at $18,874,000 after buying an additional 1,679,553 shares in the last quarter. Rafferty Asset Management LLC raised its position in shares of Replimune Group by 148.1% in the fourth quarter. Rafferty Asset Management LLC now owns 463,397 shares of the company’s stock worth $3,906,000 after acquiring an additional 276,596 shares during the period. Finally, Clearbridge Investments LLC boosted its stake in shares of Replimune Group by 2.7% during the 1st quarter. Clearbridge Investments LLC now owns 277,969 shares of the company’s stock worth $2,271,000 after acquiring an additional 7,274 shares in the last quarter. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Replimune Group Trading Down 1.1 %

REPL stock opened at $11.56 on Friday. Replimune Group, Inc. has a 12 month low of $4.92 and a 12 month high of $16.70. The company has a current ratio of 13.46, a quick ratio of 13.46 and a debt-to-equity ratio of 0.16. The firm has a 50-day moving average of $10.48 and a two-hundred day moving average of $8.62.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.78) EPS for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.10. As a group, equities research analysts expect that Replimune Group, Inc. will post -3.11 EPS for the current fiscal year.

Insider Buying and Selling at Replimune Group

In related news, CFO Emily Luisa Hill sold 8,938 shares of Replimune Group stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $10.18, for a total value of $90,988.84. Following the completion of the sale, the chief financial officer now owns 101,057 shares in the company, valued at approximately $1,028,760.26. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 20.60% of the company’s stock.

Analyst Ratings Changes

REPL has been the subject of several recent analyst reports. Roth Capital upgraded Replimune Group to a “strong-buy” rating in a research note on Tuesday, August 27th. Roth Mkm assumed coverage on Replimune Group in a research note on Tuesday, August 27th. They set a “buy” rating and a $17.00 target price for the company. HC Wainwright reissued a “buy” rating and issued a $17.00 price target on shares of Replimune Group in a research note on Monday, September 16th. Finally, JPMorgan Chase & Co. upped their price target on shares of Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 24th. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $16.80.

Replimune Group Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.